Pharma, Biotech and Pre-patent IP
Pharmaceutical and biotech firms hold molecular structures, trial protocols and synthesis routes that are worth billions long before a single patent is filed. They want AI that can mine decades of proprietary lab notes and failed trials to surface new formulations, but the cloud is barred because routing pre-patent assets through third-party processors opens a clear espionage and prior-disclosure vector. Mickai brings every retrieval and reasoning capability in-house, onto hardware the customer owns, under keys it holds. The data never leaves the building, no third party ever sees it, and the system runs independent of the internet and cloud vendors.
Heads of R&D, IP and information security at pharma and biotech firms responsible for protecting pre-patent assets.
Molecular structures, trial protocols and synthesis routes are billion-pound assets that risk espionage or prior disclosure the moment they touch the cloud before patents file.
Air-gapped retrieval and reasoning over decades of proprietary lab notes and failed trials, on hardware the customer owns under keys it holds.
New formulations are discovered and old failures are mined for insight with no early exposure of patentable assets, because what happens in the server room stays in the server room.
Five advantages hold across every sector, and they are architectural, not promotional. The third-party cloud-exposure vector is removed; your own physical, insider, and compliance controls remain yours.
The data never leaves your hardware, so no third party and no cloud-provider employee ever sees it. What happens in the server room stays in the server room.
You own the compute and the capability, so the system runs independent of the internet and of any cloud vendor's pricing, terms, or availability.
The data never crosses a geographical or digital border because it never leaves the building, which removes the cross-border-transfer and third-party-processing friction of UK GDPR, Schrems II, and the sector rules. You keep your own obligations.
Fine-tune and run retrieval on your deepest archives to build a hyper-customised co-pilot, with no risk of your proprietary edge training a public model or leaking.
After the hardware and licence, queries cost essentially electricity. A capital asset you own and depreciate, instead of volatile per-token cloud bills.
There is no third-party cloud path, so no competitor and no vendor insider can scrape, intercept, or subpoena your prompts or your fine-tuned weights from the internet. The trust vault is closed by architecture.
You own the software snapshot on your own hardware, so a change to a cloud vendor's terms, a model deprecation, or an outage cannot reach you. The system stays predictable and auditable on-premise as the rules evolve.
The specific rules that bar mainstream cloud AI from this sector's regulated data. Each one demands a named, auditable perimeter the operator controls, which a shared multi-tenant cloud cannot give.
The kind of organisation this serves, named illustratively from public information to characterise the market. These are target profiles, not customers: Mickai has no relationship, engagement, trial, or endorsement with any of them.
The enterprise studios that lead in this sector, drawn from the eighteen that sit on the one sovereign substrate. Each runs on hardware the organisation owns, under one set of operator-held keys, writing to one Open Audit Record.
Contract Review and Legal-Ops
Contract review and legal-ops over CDAs, licensing terms and collaboration agreements, all reasoned on-premises so deal-stage IP and obligations never touch an external processor.
Executive BI
Executive BI across pipeline, trial outcomes and portfolio risk, keeping board-level discovery intelligence inside the firm rather than on a vendor dashboard.
Compliance and Regulator Mode
Compliance and Regulator Mode aligned to GxP, 21 CFR Part 11 and EMA evidence, producing audit-ready records without exporting them; the customer keeps its own regulatory obligations.
Audit
Audit over lab notes, batch records and trial documentation, giving traceable retrieval across decades of proprietary and failed-trial data that stays air-gapped.
Sovereign Meeting Note-Taker
Sovereign meeting note-taker for research reviews, IP strategy sessions and investigator meetings, so sensitive discussion is captured on-premises and no third party ever sees it.
See all eighteen on the sovereign services catalogue.
Drug discovery and trial design are increasingly AI-driven, yet the most valuable corpus, a firm's own pre-patent chemistry and the institutional memory of what has already failed, is exactly the material that cannot be exposed to shared cloud infrastructure. That tension leaves a large, under-served demand for retrieval and reasoning that runs entirely inside the customer's own walls.
Money won, money saved, risk removed, on hardware you own.
Firms can surface new formulations and reuse decades of failed-trial knowledge with no early exposure of patentable assets, removing the cross-border-transfer and third-party-processing friction that blocks cloud AI in this sector while displacing recurring cloud-inference spend; physical and insider controls remain yours.
Map the sovereign stack to your pharma, biotech and pre-patent ip estate.
Briefings are for organisations weighing a sovereign, on-premises deployment. Tell us about your estate and we will walk the pack, the regulatory crosswalk, and the deployment that fits your estate.